Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world
- PMID: 24174581
- PMCID: PMC3821712
- DOI: 10.1212/01.wnl.0000436065.97642.d2
Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world
Abstract
Objective: Identify and validate clinically meaningful Timed 25-Foot Walk (T25FW) performance benchmarks in individuals living with multiple sclerosis (MS).
Methods: Cross-sectional study of 159 MS patients first identified candidate T25FW benchmarks. To characterize the clinical meaningfulness of T25FW benchmarks, we ascertained their relationships to real-life anchors, functional independence, and physiologic measurements of gait and disease progression. Candidate T25FW benchmarks were then prospectively validated in 95 subjects using 13 measures of ambulation and cognition, patient-reported outcomes, and optical coherence tomography.
Results: T25FW of 6 to 7.99 seconds was associated with a change in occupation due to MS, occupational disability, walking with a cane, and needing "some help" with instrumental activities of daily living; T25FW ≥8 seconds was associated with collecting Supplemental Security Income and government health care, walking with a walker, and inability to do instrumental activities of daily living. During prospective benchmark validation, we trichotomized data by T25FW benchmarks (<6 seconds, 6-7.99 seconds, and ≥8 seconds) and found group main effects on 12 of 13 objective and subjective measures (p < 0.05).
Conclusions: Using a cross-sectional design, we identified 2 clinically meaningful T25FW benchmarks of ≥6 seconds (6-7.99) and ≥8 seconds. Longitudinal and larger studies are needed to confirm the clinical utility and relevance of these proposed T25FW benchmarks and to parse out whether there are additional benchmarks in the lower (<6 seconds) and higher (>10 seconds) ranges of performance.
Figures
References
-
- Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold S. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008;14:988–991 - PubMed
-
- Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. New Engl J Med 2000;343:1430–1438 - PubMed
-
- Larocca N. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 2011;4:189–201 - PubMed
-
- Kiesseier B, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler 2012;18:914–924 - PubMed
-
- Goodman AD, Brown T, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732–738 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical